Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Progression-Free Survival (PFS) by blinded independent central review (BICR) of IDE196 + Crizotinib compared to investigator's choice of treatment Measure: Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment. After: Measure: Phase 2a: To determine the optimal dose of IDE196 + Crizotinib combination for Phase 2B and Phase 3 by evaluating the following: Measure: Phase 2 Progression-Free Survival (PFS) Measure: Phase 3 Overall Survival (OS) of IDE196 + Crizotinib compared to investigator's choice of treatment..
Recruitment status changed
Before: Recruiting. After: Active not recruiting.